- Home
- AKRO vs LNTH Comparison
AKRO vs LNTH Comparison
Compare AKRO & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- LNTH
- Stock Information
- Founded
- AKRO 2017
- LNTH 1956
- Country
- AKRO United States
- LNTH United States
- Employees
- AKRO N/A
- LNTH N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AKRO Health Care
- LNTH Health Care
- Exchange
- AKRO Nasdaq
- LNTH Nasdaq
- Market Cap
- AKRO 3.7B
- LNTH 3.6B
- IPO Year
- AKRO 2019
- LNTH 2015
- Fundamental
- Price
- AKRO $46.50
- LNTH $53.15
- Analyst Decision
- AKRO Strong Buy
- LNTH Buy
- Analyst Count
- AKRO 8
- LNTH 6
- Target Price
- AKRO $80.38
- LNTH $74.50
- AVG Volume (30 Days)
- AKRO 1.2M
- LNTH 1.4M
- Earning Date
- AKRO 11-07-2025
- LNTH 11-05-2025
- Dividend Yield
- AKRO N/A
- LNTH N/A
- EPS Growth
- AKRO N/A
- LNTH N/A
- EPS
- AKRO N/A
- LNTH 3.77
- Revenue
- AKRO N/A
- LNTH $1,520,653,000.00
- Revenue This Year
- AKRO N/A
- LNTH N/A
- Revenue Next Year
- AKRO N/A
- LNTH $2.91
- P/E Ratio
- AKRO N/A
- LNTH $14.19
- Revenue Growth
- AKRO N/A
- LNTH 5.75
- 52 Week Low
- AKRO $21.34
- LNTH $47.25
- 52 Week High
- AKRO $58.40
- LNTH $118.21
- Technical
- Relative Strength Index (RSI)
- AKRO 47.87
- LNTH 37.44
- Support Level
- AKRO $45.20
- LNTH $49.75
- Resistance Level
- AKRO $47.40
- LNTH $53.97
- Average True Range (ATR)
- AKRO 1.46
- LNTH 1.52
- MACD
- AKRO 0.06
- LNTH 0.44
- Stochastic Oscillator
- AKRO 34.90
- LNTH 2.78
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.